New treatments for deadly snake bites, and a fusion company that wants to get in the medical isotopes game
Jul 18, 2024
auto_awesome
Ph.D. candidate Tian Du discusses finding antivenom treatments by screening human genes for deadly snake bites, specifically targeting spitting cobra venom. A fusion company plans to use high-energy neutrons from fusion reactors for medical isotopes before transitioning to energy sales. The podcast explores innovative approaches to medical isotopes, challenges in current antivenom production, and potential treatments using CRISPR and heparin to counter snake venom toxicity.
Fusion company focuses on using high-energy neutrons from reactors for medical isotopes and X-ray imaging.
Research explores CRISPR screening to identify human genes for potential antivenom development against snake venoms.
Deep dives
NOLSTER's Biomedical Research Focus
NOLSTER specializes in researching postbiotic gut microbiota metabolite-based pharmaceuticals for treating metabolic and immune-related diseases. Products include GMP bacteria preparations and QMEC, a unique postbiotics healthcare supplement. Analytical services offered cover liquid chromatography, mass spectroscopy metabolic analysis, and advanced genetic sequencing for gut microbiota. NOLSTER's dedication to innovative research aims to address ongoing health challenges.
Shine Technologies' Fusion Approach
Shine Technologies focuses on leveraging fusion technology differently by aiming to utilize high-energy neutrons from fusion reactors for medical isotopes and X-ray imaging. By redirecting their focus from energy production to marketing byproducts like energetic neutrons, Shine plans to establish revenue streams. They have successfully applied neutron imaging for machine part inspection and are venturing into producing medical isotopes for imaging and cancer treatment.
Research on Antivenom Treatment for Snake Bites
Researcher Tien Du explores a CRISPR whole-genome screening approach to identify human genes interacting with snake venoms for potential antivenom development. By targeting genes that facilitate venom-cell interactions, such as heparin-related molecules, the study reveals promising venom treatment prospects. Recognizing the essential role of diverse genetic screening in developing effective snakebite remedies, this research emphasizes the significance of genetic diversity in enhancing healthcare outcomes.
First up this week, Staff Writer Adrian Cho talks with host Sarah Crespi about a fusion company that isn’t aiming for net energy. Instead, it’s looking to sell off the high-energy neutrons from its fusion reactors for different purposes, such as imaging machine parts and generating medical isotopes. In the long run, the company hopes to use money from these neutron-based enterprises for bigger, more energetic reactors that may someday make fusion energy.
Next, we hear from Tian Du, a Ph.D. candidate in the Dr John and Anne Chong Lab for Functional Genomics at the University of Sydney. She talks about finding antivenom treatments by screening all the genes in the human genome. Her Science Translational Medicine paper focuses on a strong candidate for treating spitting cobra bites, but the technique may prove useful for many other venomous animal bites and stings, from jellyfish to spiders.
This week’s episode was produced with help from Podigy.